Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world effectiveness of dupilumab in a European cohort of CRSwNP (CHRINOSOR).
Seys SF, Schneider S, de Kinderen J, Reitsma S, Cavaliere C, Tomazic PV, Morgenstern C, Mortuaire G, Wagenmann M, Bettio G, Ciofalo A, Diamant Z, Eckl-Dorna J, Fokkens WJ, Holzmeister C, Mariën G, Masieri S, Otten J, Scheckenbach K, Tu A, Bachert C; CHRINOSOR consortium. Seys SF, et al. Among authors: eckl dorna j. J Allergy Clin Immunol. 2024 Oct 30:S0091-6749(24)01160-6. doi: 10.1016/j.jaci.2024.10.016. Online ahead of print. J Allergy Clin Immunol. 2024. PMID: 39486595
Patient-reported disease control versus overall symptom severity as global metrics of chronic rhinosinusitis disease status.
Cotter RA, Garcia JT, Alsayed A, Schneider S, Liu DT, Eckl-Dorna J, Houssein FA, Boparai RS, Parail NA, Chu MM, Meier JC, Alsaleh S, Phillips KM, Sedaghat AR. Cotter RA, et al. Among authors: eckl dorna j. Int Forum Allergy Rhinol. 2024 Sep 13. doi: 10.1002/alr.23435. Online ahead of print. Int Forum Allergy Rhinol. 2024. PMID: 39269197
Trimeric Bet v 1-specific nanobodies cause strong suppression of IgE binding.
Bauernfeind C, Zettl I, Ivanova T, Goryainova O, Weijler AM, Pranz B, Drescher A, Focke-Tejkl M, Pavkov-Keller T, Eckl-Dorna J, Tillib SV, Flicker S. Bauernfeind C, et al. Among authors: eckl dorna j. Front Immunol. 2024 May 3;15:1343024. doi: 10.3389/fimmu.2024.1343024. eCollection 2024. Front Immunol. 2024. PMID: 38784378 Free PMC article.
Coupling of a Major Allergen to the Surface of Immune Cells for Use in Prophylactic Cell Therapy for the Prevention of IgE-Mediated Allergy.
Mengrelis K, Niederacher G, Prickler L, Kainz V, Weijler AM, Rudolph E, Stanek V, Eckl-Dorna J, Baranyi U, Spittler A, Focke-Tejkl M, Bohle B, Valenta R, Becker CFW, Wekerle T, Linhart B. Mengrelis K, et al. Among authors: eckl dorna j. Cells. 2024 Mar 3;13(5):446. doi: 10.3390/cells13050446. Cells. 2024. PMID: 38474409 Free PMC article.
Nasal IL-13 production identifies patients with late-phase allergic responses.
Campion NJ, Villazala-Merino S, Thwaites RS, Stanek V, Killick H, Pertsinidou E, Zghaebi M, Toth J, Fröschl R, Perkmann T, Gangl K, Schneider S, Ristl R, Scott IC, Cohen ES, Molin M, Focke-Tejkl M, Regelsberger G, Hansel TT, Valenta R, Niederberger-Leppin V, Eckl-Dorna J. Campion NJ, et al. Among authors: eckl dorna j. J Allergy Clin Immunol. 2023 Nov;152(5):1167-1178.e12. doi: 10.1016/j.jaci.2023.06.026. Epub 2023 Aug 1. J Allergy Clin Immunol. 2023. PMID: 37536510 Free article. Clinical Trial.
65 results